Amgen wants in on the booming weight loss drug market — and it's taking a different approach
Publishing timestamp: 2024-03-24 08:26:08
Summary
Amgen is testing a new monthly injection for weight loss that works differently from its competitors, potentially helping patients maintain weight loss even after they stop taking it. The company's drug, MariTide, is still in early stages of testing, but initial data looks promising. The drug is being compared to existing weight loss injections like Wegovy and Zepbound, with Amgen's approach focusing on blocking a hormone receptor rather than activating it. The company's longer-term phase two trial will provide more clarity on the drug's effectiveness and side effects.
Sentiment: NEUTRAL
Tickers: NVO, AMGN, NOVO.B-DK, LLY,
Keywords: novo nordisk a/s, health care industry, business news, amgen inc, pharmaceuticals, biotechnology, science, biotech and pharmaceuticals, eli lilly and co, business,
Source: https://www.cnbc.com/2024/03/24/amgen-aims-to-enter-weight-loss-drug-market-with-a-new-approach.html